HR-NBL3
Planned international multicenter, open-label, randomized modular phase III successor trial to HR2 to improve patient outcomes and decrease toxicities for patients with front-line high-risk neuroblastoma building on results from HR2 and pilot trials.
Chief Investigator: tbc
Sponsor: tbc
Funders / Charity: SIOPEN, Solving Kids Cancer
This study aims to improve the outcome for patients with newly diagnosed high-risk neuroblastoma.
Planned international multicenter, open-label, randomized modular phase III successor trial to HR2 to improve patient outcomes and decrease toxicities for patients with front-line high-risk neuroblastoma building on results from HR2 and pilot trials.
It is planned that the study will be open in all SIOPEN countries and planned recruitment is still pending to be determined.
This study is still in set-up phase.
